Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Jazz Pharmaceuticals will pay roughly $1 billion in cash to acquire Gentium, an Italian biotech firm focused on treating rare diseases. Gentium recently received European regulatory approval for Defitelio, a treatment for a condition in which veins in the liver are blocked in people undergoing a stem cell transplant. Jazz says the purchase complements its oncology and hematology portfolio. The deal is expected to close in the first quarter.
This article has been sent to the following recipient: